National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD, USA; 2007.

British Thoracic Society Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. Thorax. 2008;63(Suppl 4):iv1-121.

Article  Google Scholar 

Mauer Y, Taliercio RM. Managing adult asthma: The 2019 GINA guidelines. Cleve Clin J Med. 2020;87(9):569–75.

Article  PubMed  Google Scholar 

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2021 Report.

Mirza S, Clay RD, Koslow MA, Scanlon PD. COPD Guidelines: A Review of the 2018 GOLD Report. Mayo Clin Proc. 2018;93(10):1488–502.

Article  PubMed  Google Scholar 

Rogliani P, Ora J, Puxeddu E, Cazzola MJIjocopd. Airflow obstruction: is it asthma or is it COPD? Int J Chron Obstruct Pulmon Dis. 2016;11:3007–13.

Article  PubMed  PubMed Central  Google Scholar 

Miller-Larsson A, Selroos O. Advances in asthma and COPD treatment: combination therapy with inhaled corticosteroids and long-acting beta 2-agonists. Curr Pharm Des. 2006;12(25):3261–79.

Article  CAS  PubMed  Google Scholar 

Lalloo UG, Malolepszy J, Kozma D, Krofta K, Ankerst J, Johansen B, et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest. 2003;123(5):1480–7.

Article  CAS  PubMed  Google Scholar 

Stoloff S, Poinsett-Holmes K, Dorinsky PM. Combination therapy with inhaled long-acting beta2-agonists and inhaled corticosteroids: a paradigm shift in asthma management. Pharmacotherapy. 2002;22(2):212–26.

Article  CAS  PubMed  Google Scholar 

Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 1996;153(5):1481–8.

Article  CAS  PubMed  Google Scholar 

U.S. Food and Drug Administration. Drug Approval Package. Ellipta (fluticasone furoate and vilanterol trifenatate) Inhalation Powder. 2013. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204275Orig1s000TOC.cfm. Accessed 01 Oct 2021.

Covelli H, Pek B, Schenkenberger I, Scott-Wilson C, Emmett A, Crim C. Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. Int J Chron Obstruct Pulmon Dis. 2016;11:1–12.

CAS  PubMed  Google Scholar 

Furuhashi K, Fujisawa T, Hashimoto D, Kamiya Y, Yasui H, Karayama M, et al. Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial. J Asthma Allergy. 2019;12:253–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

GSK study 204674 protocol. https://www.gsk-studyregister.com/en/trial-details/?id=204674#documents-section. Accessed 01 June 2023.

Gross AS, Goldfrad C, Hozawa S, James MH, Clifton CS, Sugiyama Y, et al. Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trials. BMC Pulm Med. 2015;15:165.

Article  PubMed  PubMed Central  Google Scholar 

Ishiura Y, Fujimura M, Shiba Y, Ohkura N, Hara J, Kasahara K. A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in asthma-COPD overlap syndrome. Pulm Pharmacol Ther. 2015;35:28–33.

Article  CAS  PubMed  Google Scholar 

Lin J, Kang J, Lee SH, Wang C, Zhou X, Crawford J, et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respir Med. 2015;109(1):44–53.

Article  PubMed  Google Scholar 

Lin J, Tang H, Chen P, Wang H, Kim MK, Crawford J, et al. Efficacy and safety evaluation of once-daily fluticasone furoate/vilanterol in Asian patients with asthma uncontrolled on a low- to mid-strength inhaled corticosteroid or low-dose inhaled corticosteroid/long-acting beta2-agonist. Allergy Asthma Proc. 2016;37(4):302–10.

Article  CAS  PubMed  Google Scholar 

Zheng J, de Guia T, Wang-Jairaj J, Newlands AH, Wang C, Crim C, et al. Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Curr Med Res Opin. 2015;6:1191–200.

Article  Google Scholar 

Rodrigo GJ, Plaza V. Once-daily fluticasone furoate and vilanterol for adolescents and adults with symptomatic asthma: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2016;116(6):565–70.

Article  CAS  PubMed  Google Scholar 

Busse WW, O’Byrne PM, Bleecker ER, Lötvall J, Woodcock A, Andersen L, et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial. Thorax. 2013;68(6):513–20.

Article  PubMed  Google Scholar 

Woodcock A, Vestbo J, Bakerly ND, New J, Gibson JM, McCorkindale S, et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Lancet. 2017;390(10109):2247–55.

Article  CAS  PubMed  Google Scholar